GlaxoSmithKline unveils positive data from COPD studies

GlaxoSmithKline (GSK) and partner Theravance on Wednesday unveiled positive data from two of their studies into the efficacy and safety of their Incruse Ellipta product, which is being developed for the treatment of chronic obstructive pulmonary disease (COPD). The results are from two phase three studies, which have shown that COPD patients given Incruse Ellipta alongside a second Ellipta drug, known as Relvar/Breo, have additional improvement in lung function compared to those taking it alongside a placebo. GSK said the data shows a "statistically significant" improvement in lung function, and as such provide "an important addition to the evidence base supporting the efficacy and safety of Incruse"."These studies are also the first to investigate the combined effect of two of the newest medicines from our respiratory portfolio, both of which provide 24 hour efficacy," Darrell Baker, GSK's Head of Global Respiratory Franchise, said. "We will continue to progress our research to expand our understanding of how the combined use of these medicines may provide physicians with another treatment approach to meet the individual needs of their patients."Shares had risen 0.19% to 1,608.50p by 13:13. NR